Stem Cell Treatment for Multiple Sclerosis (MS) in Republic of Korea — Get 3 Top Clinic Matches with Costs

Human leukocyte antigen (HLA) matching is not required for umbilical cord mesenchymal stem cell (MSC) treatments for multiple sclerosis in South Korea. These cells possess immune privilege, meaning they lack the markers usually recognized by a patient's immune system as foreign or harmful.

• Low immunogenicity: Umbilical cord MSCs express minimal major histocompatibility complex molecules.
• Immune privilege: The recipient's body generally does not attack these allogeneic cells.
• Reduced rejection risk: Minimal immune response bypasses the clinical need for pre-treatment matching.
• Screening focus: Korean clinics prioritize cell regenerative capacity and anti-inflammatory potential instead.

Bookimed Expert Insight: While South Korea ranks in the top five global destinations for stem cell therapy, RE:YOUTH clinic limits intake to only two patients daily. This low patient volume allows medical teams to focus on precise arterial infusion techniques. This method delivers cells directly to the target area rather than via a standard IV drip.

Patient Consensus: Patients emphasize verifying if a clinic uses cord-tissue stromal cells or cord-blood hematopoietic cells. They also note that even without HLA matching, clinical risks like thrombosis still require neurologist consultation.

South Korean clinics use stem cells to modulate the immune system and reduce central nervous system inflammation. Specialized centers employ autologous mesenchymal stem cells (MSCs) and hematopoietic stem cell transplantation (HSCT) to calm hyperactive T-cells, aiming to stabilize the disease and stop new lesion formation.

• Immune system reset: HSCT uses chemotherapy to remove dysfunctional cells before rebuilding with healthy stem cells.
• Arterial delivery: RE:YOUTH clinic uses direct arterial infusion to target cells toward brain lesions.
• Regulatory oversight: The Ministry of Food and Drug Safety (MFDS) regulates all cell expansion protocols.
• Neuroprotection: Mesenchymal cells release trophic factors to protect nerve cells from ongoing autoimmune damage.

Bookimed Expert Insight: While many countries only offer standard IV infusions, South Korean centers like RE:YOUTH specialize in arterial stem cell therapy. This method delivers cells closer to the central nervous system. Because this clinic limits intake to two patients daily, patients receive highly focused care that larger hospitals often lack.

Patient Consensus: Patients emphasize the need to distinguish between immune-resetting HSCT and regenerative infusions. Verify if a facility uses MS-specific protocols or just generic injections before beginning treatment.

Patients receiving stem cell treatment for multiple sclerosis in South Korea can expect disease stabilization, reduced neuroinflammation, and fewer clinical relapses. Outcomes typically focus on slowing progression through immunomodulation and direct arterial infusion techniques in facilities regulated by the Korea Institute for Healthcare Accreditation.

• Disease stabilization: MRI scans often show fewer new inflammatory lesions after successful cell-based intervention.
• Motor function: Early-stage patients report improved walking speed, better endurance, and reduced muscle spasticity.
• Symptom relief: Improvements in bladder control and chronic fatigue are common functional outcomes.
• Immunomodulation: Mesenchymal stem cells help suppress autoreactive cells to prevent further myelin sheath breakdown.

Bookimed Expert Insight: South Korea offers a unique delivery method called direct arterial infusion at specialized centers like RE:YOUTH. While most global clinics use standard IV drips, this arterial approach aims for higher cell concentration near the target areas. The clinic strictly limits intake to two patients daily, suggesting a focus on precise delivery over patient volume.

Patient Consensus: Realistically, benefits manifest gradually over 1 to 2 years rather than overnight. Success is often defined as freedom from new neurological damage rather than a complete reversal of long-standing physical symptoms.

South Korean clinics use mesenchymal stem cells (MSCs) and hematopoietic stem cells to treat multiple sclerosis. These include allogeneic cells from umbilical cords and autologous cells from bone marrow or fat tissue. Specialized centers like RE:YOUTH also use arterial stem cell infusion to target damaged neural areas.

• Mesenchymal stem cells: These adult cells help calm immune responses and promote neural healing.
• Umbilical cord source: Allogeneic cells require no HLA matching and carry a low rejection risk.
• Autologous HSCT: Hematopoietic cells rebuild the immune system after intensive conditioning chemotherapy treatments.
• Arterial infusion: Direct arterial delivery aims to increase cell concentration in affected brain zones.

Bookimed Expert Insight: South Korea offers a rare approach called arterial stem cell therapy. RE:YOUTH in Cheonan is the only clinic providing this. They limit patient intake to 2 daily for focused care. This specialized method targets vascular delivery rather than standard intravenous routes used elsewhere.

Patient Consensus: It is vital to distinguish between HSCT using chemotherapy and experimental MSC infusions. Patients emphasize checking clinical trial data and choosing KOIHA-accredited institutions for safety.

South Korean clinics administer stem cells for multiple sclerosis using intravenous infusion, direct arterial infusion, and intrathecal injection. Specialized centers like RE:YOUTH use arterial routes, while major hospitals perform autologous hematopoietic stem-cell transplantation (aHSCT) involving chemotherapy to reset the immune system.

• Intravenous infusion: Standard systemic delivery allowing cells to reach inflammation sites through blood circulation.
• Arterial infusion: Direct delivery into arteries to target specific regions with higher cell concentrations.
• Intrathecal injection: Lumbar puncture administration bypassing the blood-brain barrier for central nervous system access.
• aHSCT protocol: Immune reset combining chemotherapy conditioning with reinfusion of harvested patient stem cells.

Bookimed Expert Insight: While most global centers focus on standard IV drips, South Korea offers unique arterial infusion technologies at clinics like RE:YOUTH. This method aims for better localized delivery. Bookimed data shows these specialized centers often limit intake to 2 patients daily to maintain quality standards.

Patient Consensus: Patients often seek aHSCT as a primary way to reset their immune system. They highlight that chemotherapy is a major part of the process, and stem cells primarily help the body recover after treatment.